BIO-PATH HOLDINGS INC (BPTH) Stock Price, Quote, News and Overview
NASDAQ:BPTH - Nasdaq - US09057N4097 - Common Stock - Currency: USD
BPTH Quote, Performance and Key Statistics
0.21
-0.42 (-66.84%)
The current stock price of BPTH is 0.21 USD. In the past month the price decreased by -74.39%. In the past year, price decreased by -96.41%.
BPTH Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About BPTH
Company Profile
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). The company is headquartered in Bellaire, Texas and currently employs 10 full-time employees. The company went IPO on 2006-01-11. The firm is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.
Company Info
BIO-PATH HOLDINGS INC
4710 Bellaire Boulevard, Suite 210
Bellaire TEXAS 77401 US
CEO: Peter H. Nielsen
Employees: 10
Company Website: https://www.biopathholdings.com/
Investor Relations: http://www.biopathholdings.com/investors/
Phone: 18327421357
BIO-PATH HOLDINGS INC / BPTH FAQ
What is the stock price of BIO-PATH HOLDINGS INC today?
The current stock price of BPTH is 0.21 USD. The price decreased by -66.84% in the last trading session.
What is the ticker symbol for BIO-PATH HOLDINGS INC stock?
The exchange symbol of BIO-PATH HOLDINGS INC is BPTH and it is listed on the Nasdaq exchange.
On which exchange is BPTH stock listed?
BPTH stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIO-PATH HOLDINGS INC stock?
7 analysts have analysed BPTH and the average price target is 12.24 USD. This implies a price increase of 5728.57% is expected in the next year compared to the current price of 0.21. Check the BIO-PATH HOLDINGS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIO-PATH HOLDINGS INC worth?
BIO-PATH HOLDINGS INC (BPTH) has a market capitalization of 905.10K USD. This makes BPTH a Nano Cap stock.
How many employees does BIO-PATH HOLDINGS INC have?
BIO-PATH HOLDINGS INC (BPTH) currently has 10 employees.
Should I buy BIO-PATH HOLDINGS INC (BPTH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BPTH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BPTH, evaluating the profitability, health, valuation and growth aspects
- BIO-PATH HOLDINGS INC (BPTH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIO-PATH HOLDINGS INC (BPTH) Sales and EPS estimates to see what analysts future expectations are.
- BIO-PATH HOLDINGS INC (BPTH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIO-PATH HOLDINGS INC (BPTH) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIO-PATH HOLDINGS INC (BPTH) Stock Chart to make your own analysis
- BIO-PATH HOLDINGS INC (BPTH) Latest news and press-releases to stay up to date.
Does BIO-PATH HOLDINGS INC (BPTH) stock pay dividends?
BPTH does not pay a dividend.
When does BIO-PATH HOLDINGS INC (BPTH) report earnings?
BIO-PATH HOLDINGS INC (BPTH) will report earnings on 2025-03-07, after the market close.
What is the Price/Earnings (PE) ratio of BIO-PATH HOLDINGS INC (BPTH)?
BIO-PATH HOLDINGS INC (BPTH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-13.79).
What is the Short Interest ratio of BIO-PATH HOLDINGS INC (BPTH) stock?
The outstanding short interest for BIO-PATH HOLDINGS INC (BPTH) is 1.84% of its float. Check the ownership tab for more information on the BPTH short interest.
BPTH Technical Analysis
BPTH Financial Highlights
Over the last trailing twelve months BPTH reported a non-GAAP Earnings per Share(EPS) of -13.79. The EPS increased by 66.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -354.57% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BPTH Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to BPTH. The Buy consensus is the average rating of analysts ratings from 7 analysts.